Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CRBP vs OBIO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OBIO Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 4–4 Matrix Metrics)

OBIO Overall Winner 6-Pillar Tally: CRBP 2 – 3 OBIO (1 Tie) Matrix Metrics: CRBP 4 – 4 OBIO

As of Nov 16, 2026, Orchestra BioMed Holdings, Inc. (OBIO) is the stronger overall head-to-head candidate over Corbus Pharmaceuticals Holdings, Inc. (CRBP) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). CRBP carries a Unified Composite Score of 45.0/100 (HOLD) at $3.38 (N/M Forward P/E, 0.0% operating margin), whereas OBIO carries 37.5/100 (SELL) at $7.12 (N/M Forward P/E, -195.4% operating margin).

  • Composite vs. Pillar Nuance: While CRBP currently prints a higher short-term Unified Composite Score (45.0/100 HOLD vs. OBIO 37.5/100 SELL), OBIO captures the overall institutional head-to-head verdict (4–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-195.4% vs. 0.0% operating margin) and revenue trajectory (-89.4% vs. -100.0% YoY).
  • Technical & Structure Timing Caution: CRBP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.3); meanwhile OBIO trades in a Markup technical trend (BREAKOUT options phase, RSI 69.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CRBP vs OBIO
CRBP NASDAQ
Corbus Pharmaceuticals Holdings, Inc.
Pharmaceutical Preparations
$3.38
-0.44% 1D
Market Cap $69.9M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.93β · 121% Vol
Unified Composite Score
45.0 / 100 HOLD
Tech 43.0 Fund 54.0 Flow 69.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -32.8%), weak momentum, RSI 34
RSI-14: 34.3 · SMA20: $3.83 · SMA50: $5.51
OBIO NASDAQ Head-to-Head Winner
Orchestra BioMed Holdings, Inc. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$7.12
-1.79% 1D
Market Cap $570.6M
TTM Revenue $31M
Forward P/E N/M
Beta / 30D Vol 1.15β · 82% Vol
Unified Composite Score
37.5 / 100 SELL
Tech 15.0 Fund 36.0 Flow 55.0 Mom 44.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.7% over 20 days), RSI 69
RSI-14: 69.2 · SMA20: $5.93 · SMA50: $5.90

6-Pillar Scorecard Institutional Category Breakdown (CRBP 2 – 3 OBIO)

Columns: Metric · CRBP · OBIO
1. Valuation Multiples OBIO
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 18.6x
2. Growth & Scale OBIO
Revenue Growth (YoY) -100.0% -89.4%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $31M
Market Cap $69.9M $570.6M
3. Profitability & Quality CRBP
Gross Margin N/A 99.6%
Operating Margin 0.0% -195.4%
Net Profit Margin 0.0% -182.5%
Return on Equity (ROE) -131.5% -182.3%
4. Balance Sheet & Cash Flow CRBP
Cash Generation (TTM) -$92M -$64M
Cash Flow Margin N/A N/A
Net Cash / Leverage $26M Net Cash $9.0M Net Debt (4.72x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning OBIO
Options Structure Phase BREAKDOWN BREAKOUT
Current IV / %ile 197.6% (66th %ile) 70.8% (<1st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CRBP (4) vs OBIO (4)
Institutional Metric CRBP OBIO Criterion Row Edge
Market Capitalization
Scale
$69.9M $570.6M Larger Scale OBIO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-100.0% -89.4% Higher Growth OBIO
Operating Margin (TTM)
Profitability
0.0% -195.4% Higher Margin CRBP
Net Profit Margin
Profitability
0.0% -182.5% Higher Margin CRBP
Return on Equity (ROE)
Capital Efficiency
-131.5% -182.3% Higher ROE CRBP
52-Week Range Position
Momentum
6% ($3–$13) 92% ($3–$7) Stronger Trend OBIO
Beta / 30D Volatility
Risk Regime
1.93β · 121% Vol 1.15β · 82% Vol Lower Realized Risk OBIO
Unified Institutional Score
Composite Signal
45.0 / 100 (HOLD) 37.5 / 100 (SELL) Higher Composite CRBP
Trailing 12M Revenue (USD)
Operating Scale
N/A $31M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 99.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 18.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$92M ($26M Net Cash) -$64M ($9.0M Net Debt (4.72x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OBIO +55.97 pp
CRBP: -25.33% · OBIO: +30.64%
3M Horizon OBIO +92.32 pp
CRBP: -66.52% · OBIO: +25.8%
6M Horizon OBIO +144.97 pp
CRBP: -66.08% · OBIO: +78.89%
1Y Horizon OBIO +139.84 pp
CRBP: -69.51% · OBIO: +70.33%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CRBP Revenue OBIO Revenue CRBP Op. Margin OBIO Op. Margin Margin Leader
FY2018 $0M N/A -1176.8% N/A CRBP
FY2019 $40M N/A -213.3% N/A CRBP
FY2020 $0M N/A -3119.2% N/A CRBP
FY2021 $0M N/A -6350.1% N/A CRBP
FY2022 N/A $0M N/A -924.3% OBIO
FY2023 N/A $0M N/A -1866.2% OBIO
FY2024 N/A $0M N/A -2437.5% OBIO
FY2025 N/A $30M N/A -154.7% OBIO

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CRBP BREAKDOWN
58d in phase · OBV NEUTRAL
Current IV 197.6%
IV Percentile 66th %ile
Put/Call OI Skew N/A
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CRBP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
OBIO BREAKOUT
32d in phase · OBV ACCUMULATION
Current IV 70.8%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact OBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CRBP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $69.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
OBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $570.6M market capitalization and -195.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CRBP vs OBIO Key Questions & Quantitative Answers

As of Nov 16, 2026, Orchestra BioMed Holdings, Inc. (OBIO) is the stronger overall head-to-head candidate over Corbus Pharmaceuticals Holdings, Inc. (CRBP) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). CRBP carries a Unified Composite Score of 45.0/100 (HOLD) at $3.38 (N/M Forward P/E, 0.0% operating margin), whereas OBIO carries 37.5/100 (SELL) at $7.12 (N/M Forward P/E, -195.4% operating margin). Composite vs. Pillar Nuance: While CRBP currently prints a higher short-term Unified Composite Score (45.0/100 HOLD vs. OBIO 37.5/100 SELL), OBIO captures the overall institutional head-to-head verdict (4–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-195.4% vs. 0.0% operating margin) and revenue trajectory (-89.4% vs. -100.0% YoY). Technical & Structure Timing Caution: CRBP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.3); meanwhile OBIO trades in a Markup technical trend (BREAKOUT options phase, RSI 69.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

OBIO leads the Growth & Scale pillar: CRBP posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with OBIO at -89.4% YoY revenue growth and +0.0% YoY earnings growth on $31M TTM revenue (99.6% gross margin, -195.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CRBP cumulative revenue shifted N/A while OBIO shifted N/A. In operating R&D and SG&A reinvestment, CRBP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OBIO.

OBIO screens cheaper on headline valuation multiples. CRBP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas OBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 18.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CRBP (-131.5% ROE) versus OBIO (-182.3% ROE) capital efficiency.

In options market volatility and institutional positioning, CRBP carries 197.6% implied volatility (66th %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.93β · 121% Vol realized risk). By comparison, OBIO carries 70.8% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.15β · 82% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.